MediWound Adds B. Braun Collaboration; NexoBrid Capacity Up Sixfold
MediWound added B. Braun to its Phase II diabetic foot ulcer trial, boosting EscharEx collaborators to seven and activating a 65% enrollment interim assessment. New NexoBrid facility has sixfold capacity increase pending H2 2026 clearance; Q4 revenue fell to $1.9M with net loss of $7.2M.
1. EscharEx Collaboration and Pipeline Expansion
MediWound secured a research collaboration with B. Braun for its Phase II diabetic foot ulcer study, bringing total EscharEx partners to seven alongside Coloplast, Convatec, Essity, Mölnlycke, Solventum and MIMEDX. Management plans parallel market research on pressure ulcers and aligned Phase II protocols with FDA and EMA.
2. Phase III VALUE Trial Progress
The global Phase III VALUE trial for EscharEx in venous leg ulcers is enrolling 216 patients across approximately 40 sites in the U.S. and Europe. An interim sample‐size assessment is scheduled after roughly 65% of patients complete treatment to preserve 90% statistical power, with full enrollment targeted by end‐2026.
3. NexoBrid Facility Expansion
MediWound’s expanded manufacturing site for NexoBrid is now operational and offers a sixfold increase in production capacity. Commercial release from the new facility is expected following regulatory clearances in H2 2026, supporting both civilian burn centers and national preparedness initiatives.
4. Financial Performance and Outlook
Q4 2025 revenue declined to $1.9 million from $5.8 million due to U.S. government shutdown delays, while net loss widened to $7.2 million ($0.56 per share). Full-year 2025 revenue totaled $17.0 million versus $20.2 million in 2024, with net loss narrowing to $23.9 million ($2.10 per share).